101140.KS
INBIOGEN CO.,Ltd [101140.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
101140.KS Stock Summary
In the News
101140.KS Financial details
Company Rating
Buy
Market Cap
4.67B
Income
20.29B
Revenue
7.92B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
2.27
Forward P/E
-
PEG
-0.28
P/S
0.59
P/B
0.31
P/C
-
P/FCF
-0.5
Quick Ratio
-
Current Ratio
5.91
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
319.17
EPS next Y
-
EPS next Q
-
EPS this Y
-194.15%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
8.55%
Revenue Q/Q
-34.65%
EPS Q/Q
188.61%
-
-
-
-
SMA20
-
SMA50
-
SMA100
1900%
Inst Own
-
Inst Trans
-
ROA
13%
ROE
16%
ROC
0.27%
Gross Margin
23%
Oper. Margin
517%
Profit Margin
256%
Payout
-
Shs Outstand
9.99M
Shs Float
842.35K
-
-
-
-
Target Price
-
52W Range
462.0-2650.0
52W High
+252.45%
52W Low
+1921.65%
RSI
100
Rel Volume
-
Avg Volume
271.77K
Volume
Perf Week
0%
Perf Month
0%
Perf Quarter
1900%
Perf Half Y
1900%
-
-
-
-
Beta
1.032
-
-
Volatility
0%, 0%
Prev Close
0%
Price
9340
Change
0%
101140.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 329.99 | 306.01 | 247.07 | 195.2 | 157.25 | |
| Net income per share | 72.58 | 850.81 | -1.09K | 1.75K | -1.65K | |
| Operating cash flow per share | -74.09 | -119.59 | -194.24 | -131.66 | -158.65 | |
| Free cash flow per share | -74.09 | -132.58 | -217.72 | -176.39 | -163.21 | |
| Cash per share | 908.35 | 876.06 | 1.91K | 431.18 | 128.1 | |
| Book value per share | 1.02K | 2.06K | 1.88K | 3.32K | 1.44K | |
| Tangible book value per share | 1.02K | 2.06K | 1.87K | 3.31K | 1.43K | |
| Share holders equity per share | 1.02K | 2.06K | 1.88K | 3.32K | 1.44K | |
| Interest debt per share | 0 | 441.81 | 266.09 | 321.08 | 75.36 | |
| Market cap | 117.39B | 95.55B | 216.7B | 191.15B | 56.56B | |
| Enterprise value | 116.78B | 97.39B | 212.36B | 181.41B | 49.05B | |
| P/E ratio | 70.55 | 3.51 | -4.81 | 2.03 | -0.47 | |
| Price to sales ratio | 15.52 | 9.75 | 21.21 | 18.24 | 4.96 | |
| POCF ratio | -69.1 | -24.96 | -26.98 | -27.04 | -4.92 | |
| PFCF ratio | -69.1 | -22.51 | -24.07 | -20.18 | -4.78 | |
| P/B Ratio | 5.03 | 1.45 | 2.78 | 1.07 | 0.54 | |
| PTB ratio | 5.03 | 1.45 | 2.78 | 1.07 | 0.54 | |
| EV to sales | 15.43 | 9.94 | 20.78 | 17.31 | 4.3 | |
| Enterprise value over EBITDA | 77.25 | -133.16 | -8.54 | -47.18 | 1.08 | |
| EV to operating cash flow | -68.74 | -25.44 | -26.44 | -25.66 | -4.26 | |
| EV to free cash flow | -68.74 | -22.95 | -23.59 | -19.15 | -4.14 | |
| Earnings yield | 0.01 | 0.29 | -0.21 | 0.49 | -2.12 | |
| Free cash flow yield | -0.01 | -0.04 | -0.04 | -0.05 | -0.21 | |
| Debt to equity | 0 | 0.15 | 0.06 | 0.08 | 0.02 | |
| Debt to assets | 0 | 0.11 | 0.05 | 0.05 | 0.01 | |
| Net debt to EBITDA | -0.41 | -2.51 | 0.17 | 2.53 | -0.17 | |
| Current ratio | 37.65 | 1.34 | 4.73 | 0.41 | 0.47 | |
| Interest coverage | 0 | -0.5 | -0.87 | -2.01 | 11.93 | |
| Income quality | -1.02 | -0.29 | 0.18 | -0.08 | 0.1 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.01 | 0.02 | 0.04 | 0.1 | 0.16 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0.01 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0.11 | 0.12 | 0.34 | 0.03 | |
| Capex to revenue | 0 | -0.04 | -0.1 | -0.23 | -0.03 | |
| Capex to depreciation | 0 | -1.63 | -2.19 | -2.15 | -0.23 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.29K | 6.28K | 6.8K | 11.44K | 7.31K | |
| ROIC | 0.07 | -0.06 | -0.06 | -0.03 | 0.36 | |
| Return on tangible assets | 0.07 | 0.3 | -0.47 | 0.34 | -0.85 | |
| Graham Net | 903.78 | 189.6 | 1.57K | -1.25K | -316.94 | |
| Working capital | 23.32B | 8.38B | 67.71B | -45.87B | -19.33B | |
| Tangible asset value | 23.35B | 65.87B | 77.37B | 177.56B | 103.9B | |
| Net current asset value | 22.99B | 7.76B | 66.87B | -64.55B | -20.37B | |
| Invested capital | 0 | 0.15 | 0.06 | 0.08 | 0.02 | |
| Average receivables | 0 | 1.26B | 4.16B | 6.37B | 6.38B | |
| Average payables | 603.97M | 430.04M | 495.87M | 602.43M | 477.46M | |
| Average inventory | 1.4B | 1.93B | 1.57B | 1.25B | 1.51B | |
| Days sales outstanding | 0 | 93.65 | 207.17 | 241.87 | 186.08 | |
| Days payables outstanding | 23.07 | 18.12 | 21.68 | 27.67 | 12.75 | |
| Days of inventory on hand | 93.31 | 89.09 | 39.33 | 63.47 | 63.25 | |
| Receivables turnover | 0 | 3.9 | 1.76 | 1.51 | 1.96 | |
| Payables turnover | 15.82 | 20.15 | 16.83 | 13.19 | 28.63 | |
| Inventory turnover | 3.91 | 4.1 | 9.28 | 5.75 | 5.77 | |
| ROE | 0.07 | 0.41 | -0.58 | 0.53 | -1.15 | |
| Capex per share | 0 | -13 | -23.48 | -44.73 | -4.56 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 34.92 | 34.19 | 28.85 | 13.38 | 0 | |
| Net income per share | -96.13 | -58.93 | 269.29 | 28 | 0 | |
| Operating cash flow per share | -7.65 | -106 | -7.14 | -3.22 | 0 | |
| Free cash flow per share | -8.63 | -106.31 | -7.14 | -3.22 | 0 | |
| Cash per share | 113.87 | 128.1 | 120.11 | 43.86 | 0 | |
| Book value per share | 595.33 | 1.44K | 1.64K | 981.92 | 0 | |
| Tangible book value per share | 587.77 | 1.43K | 1.64K | 979.07 | 0 | |
| Share holders equity per share | 595.33 | 1.44K | 1.64K | 981.92 | 0 | |
| Interest debt per share | 108.87 | 32.7 | 28.18 | 5.4 | 0 | |
| Market cap | 91.58B | 56.56B | 33.87B | 70.57B | 0 | |
| Enterprise value | 90.19B | 49.05B | 27.04B | 64.68B | 0 | |
| P/E ratio | -3.26 | -3.31 | 0.43 | 4.17 | 0 | |
| Price to sales ratio | 35.94 | 22.82 | 16.19 | 34.89 | 0 | |
| POCF ratio | -164.14 | -7.36 | -65.43 | -144.84 | 0 | |
| PFCF ratio | -145.34 | -7.34 | -65.43 | -144.84 | 0 | |
| P/B Ratio | 2.11 | 0.54 | 0.28 | 0.48 | 0 | |
| PTB ratio | 2.11 | 0.54 | 0.28 | 0.48 | 0 | |
| EV to sales | 35.4 | 19.78 | 12.92 | 31.98 | 0 | |
| Enterprise value over EBITDA | 21.94 | 1.4 | 2.79 | 110.61 | 0 | |
| EV to operating cash flow | -161.65 | -6.38 | -52.24 | -132.76 | 0 | |
| EV to free cash flow | -143.13 | -6.36 | -52.24 | -132.76 | 0 | |
| Earnings yield | -0.08 | -0.08 | 0.58 | 0.06 | 0 | |
| Free cash flow yield | -0.01 | -0.14 | -0.02 | -0.01 | 0 | |
| Debt to equity | 0.16 | 0.02 | 0.02 | 0 | 0 | |
| Debt to assets | 0.06 | 0.01 | 0.01 | 0 | 0 | |
| Net debt to EBITDA | -0.34 | -0.21 | -0.7 | -10.07 | 0 | |
| Current ratio | 0.25 | 0.47 | 0.67 | 5.92 | 5.91 | |
| Interest coverage | 3.7 | 58.05 | 58.62 | -18.67 | 0 | |
| Income quality | 0.02 | -0.52 | -0.04 | -0.12 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.2 | 0.15 | 0.19 | 0.99 | 1.58 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.13 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.03 | -0.01 | 0 | 0 | 0 | |
| Capex to depreciation | -0.23 | -0.06 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.13K | 1.38K | 3.16K | 786.52 | 0 | |
| ROIC | 0.02 | -0.09 | 0.1 | -0.01 | -0.01 | |
| Return on tangible assets | -0.06 | -0.03 | 0.14 | 0.03 | 0.01 | |
| Graham Net | -881.74 | -316.94 | -158.24 | 49.25 | 0 | |
| Working capital | -59.77B | -19.33B | -8.03B | 11.39B | 10.68B | |
| Tangible asset value | 42.89B | 103.9B | 118.73B | 147.94B | 149.03B | |
| Net current asset value | -60.7B | -20.37B | -8.97B | 9.85B | 8.7B | |
| Invested capital | 0.16 | 0.02 | 0.02 | 0 | 0 | |
| Average receivables | 8.95B | 7.39B | 5.67B | 5.35B | 2.59B | |
| Average payables | 497.53M | 388.01M | 384.8M | 357.81M | 127.41M | |
| Average inventory | 1.86B | 1.76B | 1.53B | 1.57B | 801.17M | |
| Days sales outstanding | 316.53 | 211.06 | 237.68 | 230.13 | 0 | |
| Days payables outstanding | 23.89 | 12.52 | 27.59 | 15.95 | 0 | |
| Days of inventory on hand | 101.45 | 62.12 | 92.01 | 100.31 | 0 | |
| Receivables turnover | 0.28 | 0.43 | 0.38 | 0.39 | 0 | |
| Payables turnover | 3.77 | 7.19 | 3.26 | 5.64 | 0 | |
| Inventory turnover | 0.89 | 1.45 | 0.98 | 0.9 | 0 | |
| ROE | -0.16 | -0.04 | 0.16 | 0.03 | 0.01 | |
| Capex per share | -0.99 | -0.31 | 0 | 0 | 0 |
101140.KS Frequently Asked Questions
What is INBIOGEN CO.,Ltd stock symbol ?
INBIOGEN CO.,Ltd is a KR stock and trading under the symbol 101140.KS
What is INBIOGEN CO.,Ltd stock quote today ?
INBIOGEN CO.,Ltd stock price is $9340 today.
Is INBIOGEN CO.,Ltd stock public?
Yes, INBIOGEN CO.,Ltd is a publicly traded company.
Company Profile
- Volume Average 271.77K
- Market Capitalization 4.67B
- CEO Mr. Moo-Hyung Choi
- Headquarters Pyeongtaek-Si,KR
- IPO Date 2008-04-02
-
Website
https://www.inbiogen.co.kr 
INBIOGEN CO.Ltd manufactures and sells footwear for children, youth, and adults in South Korea and internationally. The company markets its products under the ARTIS, SPECS, WANGJA, NEOSPEC, and CHAMPION brands. The company was formerly known as BTONE CO.,Ltd. INBIOGEN CO.Ltd was founded in 1949 and is based in Pyeongtaek, South Korea.
